Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Trial Profile

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Exenatide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EXSCEL
  • Sponsors Amylin Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 01 Feb 2018 Results evaluating risk of cardiovascular events from ELIXA, LEADER, SUSTAIN-6 and EXSCEL studies, published in the Annals of Pharmacotherapy.
    • 19 Dec 2017 Results assessing efficacy outcomes, published in the Annals of Internal Medicine.
    • 08 Nov 2017 According to an AstraZeneca media release, data from the study will be presented at the American Heart Association (AHA) Scientific Sessions 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top